Nicholas Hoffman & Company LLC. Sells 1,661 Shares of Eli Lilly and Company (NYSE:LLY)

Nicholas Hoffman & Company LLC. trimmed its position in Eli Lilly and Company (NYSE:LLY) by 14.0% in the third quarter, according to its most recent filing with the SEC. The fund owned 10,219 shares of the company’s stock after selling 1,661 shares during the period. Eli Lilly and Company accounts for approximately 0.4% of Nicholas Hoffman & Company LLC.’s investment portfolio, making the stock its 22nd biggest position. Nicholas Hoffman & Company LLC.’s holdings in Eli Lilly and Company were worth $9,054,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Lodestar Private Asset Management LLC increased its holdings in Eli Lilly and Company by 17.6% in the third quarter. Lodestar Private Asset Management LLC now owns 1,003 shares of the company’s stock valued at $888,000 after purchasing an additional 150 shares during the period. Jacobsen Capital Management increased its holdings in Eli Lilly and Company by 1.9% in the third quarter. Jacobsen Capital Management now owns 1,282 shares of the company’s stock valued at $1,136,000 after purchasing an additional 24 shares during the period. Valmark Advisers Inc. increased its holdings in Eli Lilly and Company by 4.3% in the third quarter. Valmark Advisers Inc. now owns 5,980 shares of the company’s stock valued at $5,298,000 after purchasing an additional 244 shares during the period. GW Henssler & Associates Ltd. increased its holdings in Eli Lilly and Company by 1.6% in the third quarter. GW Henssler & Associates Ltd. now owns 1,047 shares of the company’s stock valued at $928,000 after purchasing an additional 16 shares during the period. Finally, Tyche Wealth Partners LLC increased its holdings in Eli Lilly and Company by 3.7% in the third quarter. Tyche Wealth Partners LLC now owns 4,617 shares of the company’s stock valued at $4,090,000 after purchasing an additional 163 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $846.90 on Thursday. Eli Lilly and Company has a twelve month low of $547.61 and a twelve month high of $972.53. The stock’s 50 day moving average price is $916.20 and its 200-day moving average price is $865.10. The company has a market capitalization of $804.90 billion, a PE ratio of 124.73, a PEG ratio of 3.24 and a beta of 0.42. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.53 by ($0.35). The company had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The company’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same period last year, the firm posted $0.10 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 14.05 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.61%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of recent analyst reports. Guggenheim increased their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Bank of America increased their price target on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Morgan Stanley reiterated an “overweight” rating and set a $1,106.00 price target on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Finally, Barclays increased their price target on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a report on Wednesday, July 10th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,013.41.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.